The Next Generation Probiotics Market, estimated at USD 231.0 Mn in 2025, is expected to exhibit a CAGR of 11.2% and reach USD 485.7 Mn by 2032.
The market growth is driven by increasing demand for innovative and effective drugs across diverse therapeutic areas. Advances in drug discovery, biopharmaceuticals, and digital technologies are improving treatment outcomes and operational efficiency. Supportive regulations, rising R&D investments, and a strong focus on patient-centric care are creating new opportunities for pharmaceutical companies.
The increasing prevalence of obesity is expected to drive the growth of global next generation probiotics market over the forecast period. For instance, according to the data published by the Centers for Disease Control and Prevention on May 17, 2025, the obesity prevalence was 39.8% among adults aged 20 to 39 years, 44.3% among adults aged 40 to 59 years, and 41.5% among adults aged 60 and older during 2025–March 2025.
Global Next Generation Probiotics Market– Impact of Coronavirus (COVID-19) Pandemic
The COVID-19 pandemic and lockdowns in various countries across the globe have impacted the financial status of businesses across all sectors, including the private healthcare sector. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry, mainly due to strict lockdown in several regions. Private healthcare is one such sector that has been impacted significantly by the COVID-19 pandemic.
Global Next Generation Probiotics Market: Key Developments
In January 2025, Winclove Probiotics, a producer and developer of probiotic food supplements, developed Novobiome, a new platform to bring human-derived, next-generation probiotics (NGPs) to the European market. The company aims to generate €8 million (US$ 9.8 million) in turnover within the first five years of commercializing Novobiome. The Novobiome platform aims to resolve the most daunting obstacles to NGP product development and commercialization on the market.
In May 2025, Exeliom Biosciences, a pharmaceutical manufacturing company, announced the opening of a new pilot manufacturing unit for Live Biotherapeutics (LBPs) to boost the company’s research and development. An amount of US$ 2.8 million was granted by the European Innovation Council and SMEs Executive Agency (EISMEA)'s H2020 Accelerator Program to support the set up of this state-of-the-art pilot unit.
Browse 32 Market Data Tables and 26 Figures spread through 178 Pages and in-depth TOC on “Global Next Generation Probiotics Market”- Forecast to 2032, Global Next Generation Probiotics Market, by Bacterial Candidate (Akkermansia, Clostridium species, Bifidobacterium species, Lactobacillus species, and Others (Faecalibacterium, Christensenella,etc.)), by Application (Weight Management, Glucose Management, Inflammatory Bowel Diseases, and Others (Obesity, Metabolic Diseases, etc.)), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
To know the latest trends and insights prevalent in this market, click the link below: